- Board Member: Peter Barrett, Ph.D.
Dr. Barrett is a Partner at Atlas Venture, where he has been involved in the creation of numerous novel therapeutic and drug-discovery platform companies. More »
He was instrumental in the sales of Stromedix to Biogen and Novamed to SciClone Pharmaceuticals and is currently chairman of Obsidian Therapeutics, Synlogic, and Zafgen. Prior to joining Atlas in 2002, Dr. Barrett was Co-Founder, Executive Vice President, and Chief Business Officer of Celera Genomics, which completed the first successful sequencing of the human genome. He is currently Vice Chairman of the Advisory Council and Adjunct Professor at the Barnett Institute of Chemical and Biological Analysis at Northeastern University and a member of the research council at Boston Children’s Hospital. He received his B.S. in Chemistry from Lowell Technological Institute and his Ph.D. in Analytical Chemistry from Northeastern University.« Less
- Board Member: Ben Auspitz
Mr. Auspitz is a Partner at F-Prime Capital, where he focuses on therapeutics, with a particular interest in Series A and company formation. More »
He is a member of the board of directors of numerous venture-backed biopharmaceutical companies. Before joining F-Prime, he served as Therapeutic Area Head for immuno-inflammatory products at CombinatoRx, Inc., during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from assay stage into clinical studies and was co-inventor on fifteen product patents. Mr. Auspitz holds a B.A. from Harvard University.« Less
- Board Member: Rajesh Devraj, Ph.D.
Dr. Devraj has 20 years of pharmaceutical industry experience in drug discovery, preclinical and early clinical development, business development, and R&D strategy. More »
He currently serves as Co-Founder and CSO of Disarm Therapeutics and as an advisor for Atlas Venture. Prior roles have included CSO of Padlock Therapeutics, President & CEO of Euclises Pharmaceuticals, Senior Vice President of Deciphera Pharmaceuticals, Senior Vice President of Jubilant Drug Discovery & Development, and various positions of increasing responsibility at Pfizer and legacy Pharmacia and Searle companies. He received his Ph.D. in Medicinal Chemistry from Duquesne University and completed his Postdoctoral Fellowship at Purdue University.« Less
- President & CEO: Robert Jacks
Mr. Jacks has spent 18 years in the biopharmaceutical industry focused on product development, corporate strategy, business development, fund raising, commercial analysis, finance, and operations. More »
Most recently, Mr. Jacks was the President, CFO, and Co-Founder of Symbiomix Therapeutics, a venture-backed company that was sold to Lupin Pharmaceuticals, Inc., in 2017 after achieving NDA approval for Solosec®. Prior to Symbiomix, Mr. Jacks worked for several private biotechnology firms, including Tobira Therapeutics as Head of Corporate Development and ACT Biotech as Head of Business Development. Mr. Jacks also previously worked as an Entrepreneur-in-Residence for OrbiMed and as a Director of Business Development for Pfizer, where he led the Licensing Leadership Teams for Oncology and Infectious Diseases. Mr. Jacks received an M.B.A. from Columbia Business School, an M.S.E. in Civil Engineering from Stanford University, and a B.S.E. in Civil Engineering from Duke University.« Less